SABCS 2024: Highlights in breast cancer genomic testing

Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer

Patients with early-stage, HR+/HER2-negative BC may benefit from adjuvant T-AC therapy more than from TC

Postmastectomy radiotherapy in 'intermediate-risk' breast cancer does not impact overall survival

HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in high-risk HR-positive/HER2-negative eBC

Post-chemo olaparib continues to improve efficacy in gBRCApv and high-risk, HER2-negative primary breast cancer

Immediate breast surgery versus deferral of surgery in women aged 70+ years with operable breast cancer